There is considerable evidence that the immune system plays a crucial role in the clinical outcome of some molecular subtypes of breast cancer, especially the more aggressive subtypes, such as TNBC and HER2+ breast cancer [7, 12]. This evidence concerns the gene ERBB2 and breast carcinoma.